Company profile
Exploristics: intelligent clinical trial design + analysis
Exploristics transforms clinical development for life science organisations with unique proprietary software and wraparound biostatistics services.
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
RESOLUTIONS | Transaction WUYyWThXQ1dhZGlxemtjeA | Paper/PDF filed
Published 29 May 2026 01:41
AD01 | Transaction MzUyMzk0OTE4NWFkaXF6a2N4 | Paper/PDF filed
Published 29 May 2026 01:37
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
PSC01 | Transaction MzQ1NTg4NTI5M2FkaXF6a2N4
Published 20 Feb 2025 09:30
PSC07 | Transaction MzQ1NTg4NTI0NWFkaXF6a2N4
Published 20 Feb 2025 09:27
MR04 | Transaction MzQ1NTcxMTE4NGFkaXF6a2N4
Published 19 Feb 2025 05:36
RP04CS01 | Transaction MzQ0NDc3ODU0M2FkaXF6a2N4
Published 26 Nov 2024 02:20
RP04CS01 | Transaction MzQ0NDc3OTMxNGFkaXF6a2N4
Published 26 Nov 2024 02:19
CS01 | Transaction MzQxNTk3NDU0MmFkaXF6a2N4 | Paper/PDF filed
Published 27 Nov 2024 10:41
CS01 | Transaction MzI2NjEyODQzM2FkaXF6a2N4 | Paper/PDF filed
Published 27 Nov 2024 10:43
Company registered at Companies House
1 Nov 2024 to 31 Oct 2029
**The Northern Ireland Precision Biomarkers and Therapeutics Consortium (NIPBT)** is a partnership of Life and Health Science (LHS) companies and Academia, aligned to the strategies of both the Departments of Health and Economy of the NI devolved government to enhance health and wealth creation for NI citizens. Currently, NI has a significant presence in ...
1 Oct 2021 to 31 Mar 2023
Exploristics is a rapidly growing company providing data analytics products and biostatistics services to the Pharmaceutical industry. Our flagship product, KerusCloud, is a commercially available software platform that reduces the risks, costs and duration of drug development. This project aims to extend the KerusCloud capabilities by enabling and exploi...
1 Jan 2020 to 31 Jul 2021
With over 90% of new medical treatments undergoing clinical trials failing to reach the market and the cost of developing each new successful drug now estimated to be around US$3 billion, there is an urgent need for the life science industry to reduce their study failure rates to achieve a better return on investment and bring down the cost of medical int...
1 Feb 2019 to 31 Jul 2021
AI-driven business performance forecaster and planner
1 Aug 2017 to 31 Jul 2019
The project aims to develop a demonstrator of a cloud-based software and storage platform for high-dimensional biological marker (biomarker) data for use in simulating precision medicine studies. Precision medicine is a current research strategy used by the pharmaceutical industry to improve the targeting of new treatments to patients most likely to benef...
1 Mar 2016 to 28 Feb 2017
This proposal outlines a feasibility study to examine development of a novel platform for disseminating andcommercialising new study design and analysis methods applied to stratified medicine. This projects involves acollaboration between the SME Exploristics and and a software development company, Kainos. The platformwill support stratified medicine rese...
1 Apr 2014 to 31 Mar 2017
Exploristics seek to develop an innovative, new simulation platform and additional software modules which will allow users to simulate and evaluate clinical studies with multiple objectives prior to their initiation, allowing determination of the optimal design and analysis approach to meet study objectives with the minimum number of patients, and therefo...
1 Mar 2013 to 31 Oct 2013
Exploristics seek to explore and appraise the commerical potential for an innovative new simulation platform which will allow users to simulate and evaluate clinical studies with multiple objectives prior to their initiation, allowing determination of the optimal design and analysis approach to meet study objectives with the minimum number of patients, an...
